While CELMoDs frequently cause neutropenia, this effect is most pronounced in early cycles and manageable with growth factors. This contrasts sharply with the persistent, quality-of-life-impairing non-hematologic side effects of lenalidomide, such as rash and severe fatigue. This trade-off results in a significantly better long-term tolerability profile for patients.

The field of multiple myeloma has transformed from having few treatments to an abundance of effective drugs. The primary clinical challenge is no longer finding a therapy that works, but rather determining the optimal sequence and combination of available options, highlighting a unique form of market maturity.

Unlike IMiDs (lenalidomide) which only close the Cereblon E3 ligase complex by 15-20%, mezigdemide achieves 100% closure. This leads to more robust degradation of key proteins, causing powerful direct myeloma cell destruction and enhanced immune activation, earning it the nickname 'CAR T in a pill.'

Lenalidomide has a unique off-target effect on C1K alpha which clonally selects for p53 mutated cells, increasing second cancer risk. Preclinical data clearly show that CELMoDs like iberdomide and mezigdomide do not share this mechanism, offering a significant potential safety advantage over the older IMiD.

Dr. Richardson envisions iberdomide as a well-tolerated upfront and maintenance therapy due to its favorable safety profile. In contrast, the more potent mezigdomide is targeted for heavily pre-treated, relapsed/refractory patients, particularly those who have failed immunotherapies.

An expert who initially viewed CELMoDs as incremental improvements now considers them fundamentally different. The new litmus test for future myeloma trials will be tracking prior patient exposure to CELMoDs like iberdomide, just as they track prior IMiD exposure today, cementing their status as a distinct therapeutic category.

Unlike IMiDs, which only partially engage the target, CELMoDs like iberdomide are larger molecules that fully close the cereblon E3 ligase pocket. This maximizes degradation of target proteins Ikaros and Aiolos, leading to greater potency and what is described as "hitting the death star" of the myeloma cell.

For older, transplant-ineligible myeloma patients, quadruplet regimens are not administered at full strength. Clinicians proactively reduce doses of bortezomib, lenalidomide, and dexamethasone based on patient fitness and renal function to manage toxicity while maintaining efficacy.

In newly diagnosed, transplant-ineligible myeloma, an iberdomide-based triplet (Iber-Dara-Dex) achieved 64% MRD negativity. This result is described as "astounding" because achieving MRD negativity is not even a realistic goal for comparable IMiD-based triplets like Dara-Len-Dex (the MAYA regimen). This sets a dramatically higher efficacy bar for frontline treatments.